Market Intelligence, Clinical Progress, and High-Purity Reagents for Inflammatory Disease and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for IL-19 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IL-19 Recombinant Protein High purity (>95%), Endotoxin controlled (<1.0 EU/μg). Sequence Verified. HEK293 expressed for native glycosylation. |
View IL19 Products |
| Gene Delivery | IL-19 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and overexpression validation. |
View IL19 Products |
| Benchmark Ab | Anti-IL-19 Benchmark Antibody Recombinant positive control derived from clinical-stage/patent sequences. |
View IL19 Products |
| Validator | IL-19 siRNA Set For target knockdown verification and phenotypic specificity assays. |
View IL19 Products |
| Related Target A | IL-20RA (IL-20 Receptor Alpha) Primary receptor subunit involved in the IL-19 signaling complex. |
View IL20RA Products |
| Related Target B | IL-20RB (IL-20 Receptor Beta) Shared receptor subunit required for functional IL-19/IL-20R signaling. |
View IL20RB Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Receptor binding assay validation | HEK293-expressed IL-19 with native post-translational modifications to ensure correct receptor interaction. |
| IL-10 family cross-reactivity screening | Recombinant IL-20RA and IL-20RB receptor proteins available to set up highly specific counter-screens. |
| Lack of reliable positive controls | Sequence-verified clinical benchmark antibodies available as reference standards for neutralization assays. |
| Assay specificity and off-target risks | Sequence-verified siRNA knockdown tools included to validate biological readouts. |
Live IL-19 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for IL-19 therapeutics is intensifying, with major players shifting focus from traditional systemic anti-inflammatory mAbs to targeted tissue-specific blockades and combination therapies. As first-generation therapies targeting the broader IL-10 family reach the clinic, the next wave of R&D is targeting highly selective IL-19 antagonism to treat chronic inflammatory skin disorders, vascular diseases, and specific solid tumors without systemic immunosuppression.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (mAb) | Biotech & Academic Consortia | Psoriasis, Atopic Dermatitis, Rheumatoid Arthritis | Neutralization Assay (Need high-purity, native-glycosylated IL-19 protein) |
| Receptor Antagonists / Decoys | Biopharma Startups | Vascular Inflammation, Atherosclerosis | Receptor Competition Assay (Need IL-20RA & IL-20RB monomeric/heterodimeric proteins) |
| Small Molecule Inhibitors | Academic Research Institutes | Solid Tumors (Breast, Oral Cancer) | Downstream STAT3 Signaling Assays (Need Lentivirus for IL-20R1/R2 stable cell lines) |